The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The importance of improving the management of cardiotoxicity when treating CLL
Lydia Scarfò , MD, Università Vita-Salute San Raffaele, Milan, Italy, discusses the need for a deeper understanding of the mechanisms behind cardiac toxicities associated with BTK inhibitors when treating patients with chronic lymphocytic leukemia (CLL). This is important as it may allow clinicians to better select patients for therapy and improve the management of cardiac complications. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
